HNGE
Hinge Health, Inc. Information Technology Services-Computer Processing & Data Preparation Russell 3000
$114.32Close
$31.17 – $116.9052-week range
Nov 2, 2026Next report · after the close
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 99 · stronger than 99% of stocks over 12 months
- Near its high 2% below its 52-week high
- Accumulation up-day volume 1.7× down-day volume over 50 sessions
Cautions
- Extended 4.4 ATR above its 50-day average
- Results soon Nov 2, 2026, in 1 day
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
2%
1wk
up 2.5%
price change
1mo
up 17.6%
price change
12-month return
up 135%
market up 11% ·
its own up 120%
F-score
—
— Not assessed
Altman Z″
-7.51
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
—
price / book
Earnings yield
—
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
up 51%
year on year
EPS growth
—
latest quarter
Sales growth
up 53%
latest quarter · +6 pts
ROE
down 296%
return on equity
Free cash margin
up 29%
$170.7M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
Repair signals
- Gross margin 76.8% → 79.6%
Trade setup
ATR%
3.8%
$4.29 a day · 2×ATR $105.73
RS
99 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
1.5×
vs 50-day average
Up/down volume
1.66
50 sessions
Implied move
—
no option chain · report Nov 2, 2026
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
Last reported
Aug 4, 2026
Results reaction
Aug 4, 2026+2% vs market2 sessions after results
Financials
- Gross 80%
- Net -90%
- Free cash 29%
- Cash
- Long-term debt
| FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|
| Revenue | $292.7M | $390.4M | $587.9M |
| Gross margin | 66% | 77% | 80% |
| Operating income | -$130.5M | -$31.9M | -$546.4M |
| Net income | -$108.1M | -$11.9M | -$528.3M |
| Net margin | -37% | -3% | -90% |
| Earnings per share | -$8.31 | -$0.88 | -$9.68 |
| Free cash flow | -$65.9M | $48.0M | $170.7M |
| Free cash margin | -23% | 12% | 29% |
| Cash | $235.0M | $300.8M | $208.0M |
| Shareholders' equity | -$424.0M | -$434.6M | $178.7M |
| Shares outstanding | — | 16.38m | 0 |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Mar 3, 2026 | Annual ↗ | Dec 31, 2025 | 62d |
| Nov 7, 2025 | Quarterly ↗ | Sep 30, 2025 | 38d |
| Aug 11, 2025 | Quarterly ↗ | Jun 30, 2025 | 42d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 21, 2026 | Material agreement · New obligation ↗ |
| Aug 4, 2026 | Results · Regulation FD · Other events ↗ |
| Jun 9, 2026 | Regulation FD ↗ |
| Jun 4, 2026 | Shareholder vote ↗ |
| May 5, 2026 | Results · Regulation FD ↗ |
| Mar 17, 2026 | Director or officer change ↗ |
| Feb 10, 2026 | Results · Regulation FD ↗ |
| Nov 12, 2025 | Regulation FD · Other events ↗ |
| Nov 4, 2025 | Results · Regulation FD ↗ |
| Aug 13, 2025 | Other events ↗ |
| Aug 5, 2025 | Results · Regulation FD ↗ |
| May 23, 2025 | Charter or bylaws · Other events ↗ |